Noticias de ARWR_US

Mercado

Noticias del mercado

Últimas noticias sobre ARWR_US — 172 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ARWR_US ✕ 172 resultados

16/09/2026 ARWR_US — Yahoo Finance

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts

16/09/2026 ARWR_US — Intellectia AI

Arrowhead Pharmaceuticals Plans Supplemental Drug Approval Application

16/09/2026 ARWR_US — Bybit

Arrowhead Pharmaceuticals, Inc. rStock (RARWR) Price Prediction for 2026 to 2031

Discover how Arrowhead Pharmaceuticals, Inc. rStock (RARWR) may perform from 2026 to 2031 using historical trends and forecasts. Buy, sell, and trade on Bybit today.

16/09/2026 ARWR_US — Bybit

Arrowhead Pharmaceuticals, Inc. rStock Price: RARWR Live Price Today | RARWR Market Cap & Chart Analysis

16/09/2026 ARWR_US — Yahoo Finance

Arrowhead Achieves Clinical Validation for New Drug Platform

16/09/2026 ARWR_US — Benzinga

Arrowhead Achieves Clinical Validation for New Drug Platform

15/09/2026 ARWR_US — Yahoo Finance

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif., September 15, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP

15/09/2026 ARWR_US — Business Wire

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

15/09/2026 ARWR_US — TradingKey

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 8.93% on Sep 15: What Investors Need To Know

15/09/2026 ARWR_US — Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

15/09/2026 ARWR_US — Yahoo Finance

ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?

08/09/2026 ARWR_US — Yahoo Finance

Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target

06/09/2026 ARWR_US — Yahoo Finance

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million